Identifying Novel Pathways at the Interface of Immunity and Metabolism

We are committed to the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. The Company’s lead product candidate, BT-11, is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.

In January 2021, the Company reported initial results from its Phase 2 trial of BT-11 for patients with mild to moderate ulcerative colitis (UC). In the first half of 2021, Landos expects to initiate a Phase 3 trial of BT-11 in UC patients and plans to initiate a Phase 2 trial of BT-11 in moderate to severe Crohn’s disease (CD).

View More

Aiming to Bring Safer, More Effective Therapies to Patients with IBD

For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Our therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune diseases by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.

At Landos Biopharma, our mission is to be bold and uncover new mechanisms of treating autoimmune diseases.